Risk of radiation-induced second malignant neoplasms from photon and proton radiotherapy in paediatric abdominal neuroblastoma.
Abdominal neuroblastoma
Childhood cancer
Intensity modulated arc therapy (IMAT)
Paediatric
Pencil beam scanning
Proton therapy
Second malignant neoplasm
Journal
Physics and imaging in radiation oncology
ISSN: 2405-6316
Titre abrégé: Phys Imaging Radiat Oncol
Pays: Netherlands
ID NLM: 101704276
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
25
02
2021
revised:
28
05
2021
accepted:
18
06
2021
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
27
7
2021
Statut:
epublish
Résumé
State-of-the-art radiotherapy modalities have the potential of reducing late effects of treatment in childhood cancer survivors. Our aim was to investigate the carcinogenic risk associated with 3D conformal (photon) radiation (3D-CRT), intensity modulated arc therapy (IMAT) and pencil beam scanning proton therapy (PBS-PT) in the treatment of paediatric abdominal neuroblastoma. The risk of radiation-induced second malignant neoplasm (SMN) was estimated using the concept of organ equivalent dose (OED) for eleven organs (lungs, rectum, colon, stomach, small intestine, liver, bladder, skin, central nervous system (CNS), bone, and soft tissues). The risk ratio (RR) between radiotherapy modalities and lifetime absolute risks (LAR) were reported for twenty abdominal neuroblastoma patients (median, 4y; range, 1-9y) historically treated with 3D-CRT that were also retrospectively replanned for IMAT and PBS-PT. The risk of SMN due to primary radiation was reduced in PBS-PT against 3D-CRT and IMAT for most patients and organs. The RR across all organs ranged from 0.38 ± 0.22 (bladder) to 0.98 ± 0.04 (CNS) between PBS-PT and IMAT, and 0.12 ± 0.06 (rectum and bladder) to 1.06 ± 0.43 (bone) between PBS-PT and 3D-CRT. The LAR for most organs was within 0.01-1% (except the colon) with a cumulative risk of 21 ± 13%, 35 ± 14% and 35 ± 16% for PBS-PT, IMAT and 3D-CRT, respectively. PBS-PT was associated with the lowest risk of radiation-induced SMN compared to IMAT and 3D-CRT in abdominal neuroblastoma treatment. Other clinical endpoints and plan robustness should also be considered for optimal plan selection.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
State-of-the-art radiotherapy modalities have the potential of reducing late effects of treatment in childhood cancer survivors. Our aim was to investigate the carcinogenic risk associated with 3D conformal (photon) radiation (3D-CRT), intensity modulated arc therapy (IMAT) and pencil beam scanning proton therapy (PBS-PT) in the treatment of paediatric abdominal neuroblastoma.
MATERIALS AND METHODS
METHODS
The risk of radiation-induced second malignant neoplasm (SMN) was estimated using the concept of organ equivalent dose (OED) for eleven organs (lungs, rectum, colon, stomach, small intestine, liver, bladder, skin, central nervous system (CNS), bone, and soft tissues). The risk ratio (RR) between radiotherapy modalities and lifetime absolute risks (LAR) were reported for twenty abdominal neuroblastoma patients (median, 4y; range, 1-9y) historically treated with 3D-CRT that were also retrospectively replanned for IMAT and PBS-PT.
RESULTS
RESULTS
The risk of SMN due to primary radiation was reduced in PBS-PT against 3D-CRT and IMAT for most patients and organs. The RR across all organs ranged from 0.38 ± 0.22 (bladder) to 0.98 ± 0.04 (CNS) between PBS-PT and IMAT, and 0.12 ± 0.06 (rectum and bladder) to 1.06 ± 0.43 (bone) between PBS-PT and 3D-CRT. The LAR for most organs was within 0.01-1% (except the colon) with a cumulative risk of 21 ± 13%, 35 ± 14% and 35 ± 16% for PBS-PT, IMAT and 3D-CRT, respectively.
CONCLUSIONS
CONCLUSIONS
PBS-PT was associated with the lowest risk of radiation-induced SMN compared to IMAT and 3D-CRT in abdominal neuroblastoma treatment. Other clinical endpoints and plan robustness should also be considered for optimal plan selection.
Identifiants
pubmed: 34307918
doi: 10.1016/j.phro.2021.06.003
pii: S2405-6316(21)00033-6
pmc: PMC8295851
doi:
Types de publication
Journal Article
Langues
eng
Pagination
45-52Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Cancer J. 2009 May-Jun;15(3):174-80
pubmed: 19556899
J Natl Cancer Inst. 2001 Apr 18;93(8):618-29
pubmed: 11309438
Med Phys. 2015 Aug;42(8):4719-26
pubmed: 26233199
Clin Oncol (R Coll Radiol). 2020 Jul;32(7):467-476
pubmed: 32081577
Radiat Res. 2011 Oct;176(4):508-20
pubmed: 21756083
Eur J Cancer. 2020 Jan;124:47-55
pubmed: 31726247
Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):244-51
pubmed: 12007965
Pediatr Blood Cancer. 2013 Oct;60(10):1606-11
pubmed: 23737005
Clin Oncol (R Coll Radiol). 2019 Mar;31(3):182-190
pubmed: 30509728
Phys Med Biol. 2014 Jun 21;59(12):2883-99
pubmed: 24828559
Future Oncol. 2012 Jul;8(7):839-58
pubmed: 22830404
J Appl Clin Med Phys. 2013 Mar 04;14(2):4139
pubmed: 23470942
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):224-33
pubmed: 23102695
Radiat Res. 2007 Jul;168(1):1-64
pubmed: 17722996
Radiother Oncol. 2008 Nov;89(2):141-9
pubmed: 18692928
J Korean Med Sci. 2009 Jun;24(3):461-7
pubmed: 19543510
Ann ICRP. 2007;37(2-4):1-332
pubmed: 18082557
Future Oncol. 2013 Mar;9(3):439-49
pubmed: 23469979
Radiat Oncol. 2013 Nov 01;8:255
pubmed: 24180282
Int J Cancer. 2003 Dec 10;107(5):791-6
pubmed: 14566829
Clin Oncol (R Coll Radiol). 2021 Mar;33(3):e132-e142
pubmed: 32962907
J Clin Oncol. 2009 May 10;27(14):2328-38
pubmed: 19332714
Med Phys. 2014 Mar;41(3):033701
pubmed: 24593745
J Radiat Res. 2017 May 1;58(3):363-371
pubmed: 27789564
J Radiol Prot. 2020 Mar;40(1):225-242
pubmed: 31509813
J Clin Oncol. 2020 Sep 1;38(25):2902-2915
pubmed: 32639845
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):170-4
pubmed: 22749633
J Clin Oncol. 2015 Sep 20;33(27):3008-17
pubmed: 26304901
Pediatr Blood Cancer. 2005 Sep;45(3):324-32
pubmed: 15714447
Theor Biol Med Model. 2011 Jul 26;8:27
pubmed: 21791103
Cancers (Basel). 2020 Jan 28;12(2):
pubmed: 32013055
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):1-7
pubmed: 16618572
Cancer Manag Res. 2014 Dec 17;7:1-11
pubmed: 25565886
Nat Rev Dis Primers. 2016 Nov 10;2:16078
pubmed: 27830764
Radiat Environ Biophys. 2009 Aug;48(3):275-86
pubmed: 19499238
Australas Phys Eng Sci Med. 2019 Mar;42(1):201-209
pubmed: 30725439
Lancet Oncol. 2017 Apr;18(4):500-514
pubmed: 28259608
J Clin Oncol. 2002 Aug 15;20(16):3484-94
pubmed: 12177110
Acta Oncol. 2005;44(4):339-47
pubmed: 16120542
Phys Med. 2017 Oct;42:221-227
pubmed: 29103987